See more : Kosmos Energy Ltd. (KOS.L) Income Statement Analysis – Financial Results
Complete financial analysis of Synaptogenix, Inc. (SNPX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Synaptogenix, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Power Financial Corporation (PWF-PZ.TO) Income Statement Analysis – Financial Results
- Nation Group (Thailand) Public Company Limited (NATION.BK) Income Statement Analysis – Financial Results
- Viomi Technology Co., Ltd (VIOT) Income Statement Analysis – Financial Results
- Resilux NV (0FSN.L) Income Statement Analysis – Financial Results
- RegTech Open Project plc (RTOP.L) Income Statement Analysis – Financial Results
Synaptogenix, Inc. (SNPX)
About Synaptogenix, Inc.
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 6.35K | 5.71K | 4.97K | 4.87K | 4.39K | 3.00K |
| Gross Profit | -6.35K | -5.71K | -4.97K | -4.87K | -4.39K | -3.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.97M | 6.32M | 4.34M | 3.07M | 5.67M | 4.89M |
| General & Administrative | 6.34M | 9.81M | 8.28M | 8.09M | 9.84M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.34M | 9.81M | 8.28M | 8.09M | 9.84M | 6.26M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 28.36K | 0.00 | 0.00 |
| Operating Expenses | 8.31M | 16.13M | 12.62M | 11.16M | 15.51M | 11.15M |
| Cost & Expenses | 8.31M | 16.13M | 12.62M | 11.16M | 15.51M | 11.15M |
| Interest Income | 1.65M | 335.04K | 7.11K | 153.21K | 378.71K | 127.11K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.35K | 5.71K | 4.97K | 4.87K | 4.39K | 3.00K |
| EBITDA | -8.31M | -16.13M | -12.61M | -11.15M | -15.51M | -11.02M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.31M | -26.36M | -12.62M | -9.46M | -15.51M | -11.15M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.28M | 10.56M | 7.11K | -1.55M | 378.71K | 127.11K |
| Income Before Tax | -6.04M | -5.57M | -12.61M | -12.70M | -15.13M | -11.02M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -115.89K | -7.11K | 1.55M | -378.71K | 1.00 |
| Net Income | -6.04M | -5.46M | -12.60M | -14.25M | -14.76M | -11.02M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -29.56 | -0.78 | -2.51 | -11.33 | -2.48 | -46.33 |
| EPS Diluted | -29.56 | -0.78 | -2.51 | -11.33 | -2.48 | -46.33 |
| Weighted Avg Shares Out | 466.08K | 6.99M | 5.02M | 1.26M | 5.95M | 237.91K |
| Weighted Avg Shares Out (Dil) | 466.08K | 6.99M | 5.02M | 1.26M | 5.95M | 237.91K |
Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
NEW YORK , March 15, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alkon, the Company's President and Chief Scientific Officer, will present recent clinical results...
Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment
SNPX did not achieve primary endpoints in two Phase 2 studies for Bryostatin for the treatment of Alzheimer's Disease in moderately severe to severe patients. Post-hoc analysis of 95 patients from these two studies with MMSE 10-15, and not taking...
5 Short Squeeze Candidates To Watch: Huadi Tops List, Altimeter Group And Bit Digital Rejoin Leaderboard
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE:GME) or AMC Entertainment Holdings Inc (NYSE:AMC). A short squeeze can occur when a heavily shorted stock rises in value instead...
Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological Diseases
Image by Gerd Altmann from Pixabay How well we think, feel and act rests in the hands of trillions of tiny connectors in our minds.
Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference
NEW YORK, Sept. 10, 2021 /PRNewswire/ -- Synaptogenix, Inc (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced it will be featured as a presenting company at the H.C.
Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome
NEW YORK, Aug. 5, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it signed a memorandum of understanding ("MOU") with the Nemours A.I. DuPont Hospital for Children, an internationally recognized...
Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021
NEW YORK, July 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that its abstract for presentation at the Alzheimer's Association International Conference (AAIC) is now available entitled "Bryostatin Restores Cognitive...
Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings
NEW YORK, July 21, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it will hold a conference call for investors to discuss its abstract presented at the Alzheimer's...
Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline
NEW YORK, July 14, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that its abstract has been accepted at the Alzheimer's Association International Conference ("AAIC"), which will be held...
Synaptogenix: The Next Big Thing In Alzheimer's
The company's Bryostatin drug is likely to read out positive data in current phase 2, despite its checkered past.
Source: https://incomestatements.info
Category: Stock Reports